Amplify Therapeutics ApS: Financial statements 2024
CVR: 43803999
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Amplify Therapeutics ApS (CVR 43803999) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -4,961,503 and a net result of DKK -7,194,854 compared with DKK -1,952,719 the year before. Equity in the 2024 report amounted to DKK -9,107,573. The company had 3 employees in the financial year.
- Gross Profit
- DKK -4,961,503
- Profit/Loss
- DKK -7,194,854
- Equity
- DKK -9,107,573
- Total Assets
- DKK 5,944,733
- Employees
- 3
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Amplify Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -1,558,702, and the net result was DKK -1,952,719.
About Amplify Therapeutics ApS
Amplify Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2023. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Thomas Kirkegaard Jensen. The board consists of Anders Mørkeberg Hinsby (chair), Anders Vadsholt and Thomas Kirkegaard Jensen. The company is owned by Alpha Healthcare Investments ApS, Dare to Dream ApS and WoB Holding ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 925,944 and a net result of DKK -3,335,844 compared with DKK -7,194,854 the year before. Equity in the 2025 report amounted to DKK -12,443,417.